

(51) International Patent Classification:
C07D 231/14 (2006.01)(21) International Application Number:
PCT/EP2011/063360(22) International Filing Date:
3 August 2011 (03.08.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/372,122 10 August 2010 (10.08.2010) US(71) Applicant (for all designated States except US): SYNGENTA PARTICIPATIONS AG [CH/CH];
Schwarzwaldallee 215, CH-4058 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WANG, Linhua [US/US]; Syngenta Crop Protection Inc., 410 Swing Road, Greensboro, North Carolina 27409 (US). SHETH, Ritesh Bharat [US/US]; Syngenta Crop Protection Inc., 410 Swing Road, Greensboro, North Carolina 27409 (US).

(74) Agent: THWAITE, Jonathan; Syngenta Crop Protection, Münchwilen AG, Schaffhauserstrasse, CH-4332 Stein (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))


Published:

— with international search report (Art. 21(3))

(54) Title: PROCESS FOR THE PREPARATION OF 3-HALOALKYLPYRAZOLES



(I)



(IV)

(57) Abstract: The present invention provides a process for the preparation of a compound of formula (I) wherein R¹ is C₁-C₄ haloalkyl; R² is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; and R³ is methyl or ethyl; comprising reacting a compound of formula (IV) wherein R¹, R² and R³ are as defined for the compound of formula I; with an alkylating agent in the presence of an amide.

PROCESS FOR THE PREPARATION OF 3-HALOALKYLPYRAZOLES

The present invention relates to N-alkylation of substituted pyrazoles. In particular, the invention relates to the isomerisation of N-alkylated substituted pyrazoles and to the preparation of selected isomers of N-alkylated substituted pyrazoles.

5


Fungicides for use in crop protection are produced on a very large scale, e.g. thousands of tons per year. Given the scale on which fungicides are produced, any improvement in the production process can represent significant cost savings.

10 N-alkylated substituted pyrazoles, for example ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (DFPE), are valuable intermediates in the preparation of a number of fungicides, including Sedaxane, Isopyrazam and others. In DFPE only one of the nitrogen atoms in the pyrazole ring is alkylated.

15 According to WO 2006/045504, regioselective N-alkylation of substituted pyrazoles may be achieved by reacting the corresponding substituted pyrazoles with trialkyl phosphates or trialkylphosphonates. However, it would be desirable to increase the yield of the non-iso isomer in order to reduce costs and wastage in commercial production.

20


In a first aspect, the invention provides a process for the preparation of a compound of formula I:



wherein R¹ is C₁-C₄ haloalkyl;

25 R² is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; and
R³ is methyl or ethyl;

comprising reacting a compound of formula IV:



wherein R^1 , R^2 and R^3 are as defined for the compound of formula I;

with an alkylating agent in the presence of an amide.

5

The compound of formula IV is referred to herein as the "iso" isomer with respect to compounds of formula I.

The alkyl groups appearing in the above substituent definitions may be straight-
 10 chain or branched and are, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl, preferably methyl or ethyl. Halogen is generally fluorine, chlorine, bromine or iodine, preferably fluorine. C_1 - C_4 haloalkyl groups are derived from the mentioned C_1 - C_4 alkyl groups and are preferably difluoromethyl or trifluoromethyl.

Aryl refers to aromatic hydrocarbon ring systems which may be a single ring or
 15 multiple rings which are fused together or linked covalently. Examples for aryl groups are phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl, anthracenyl, phenanthrenyl and biphenyl.

Heteroaryl refers to aromatic ring systems comprising mono-, bi- or tricyclic
 systems wherein at least one oxygen, nitrogen or sulfur atom is present as a ring
 20 member. Examples are furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, indolyl, benzothiophenyl, benzofuranyl, benzimidazolyl, indazolyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, phthalazinyl, quinoxalinyl, quinazolinyl, cinnolinyl and
 25 naphthyridinyl.

R^2 for example may be optionally substituted alkyl, optionally substituted aryl or
 optionally substituted heteroaryl. This means that the alkyl, aryl and heteroaryl groups
 may or may not carry one or more identical or different substituents. Normally not more
 than three substituents are present at the same time. Examples of substituents are:
 30 halogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, haloalkenyl, cycloalkenyl, alkynyl, haloalkynyl, alkoxy, haloalkoxy, cycloalkoxy, alkenyloxy, haloalkenyloxy, alkynyloxy, haloalkenyloxy, alkylthio, haloalkylthio, cycloalkylthio, alkenylthio, alkynylthio, alkylcarbonyl, haloalkylcarbonyl, cycloalkylcarbonyl, alkenylcarbonyl,

alkynylcarbonyl, alkoxyalkyl, cyano, nitro, hydroxy, mercapto, amino, alkylamino and dialkylamino.

Preferred optional substituents are C₁-C₈ alkyl, halo-C₁-C₈ alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl-C₁-C₈ alkyl, C₂-C₈ alkenyl, halo-C₂-C₈ alkenyl, C₃-C₈ cyclo-
 5 C₂-C₈ alkenyl, C₂-C₈ alkynyl, halo-C₂-C₈ alkynyl, C₁-C₈ alkoxy, halo-C₁-C₈ alkoxy, C₃-C₈ cycloalkoxy, C₂-C₈ alkenyloxy, halo-C₂-C₈ alkenyloxy, C₂-C₈ alkynyloxy, halo-C₂-C₈ alkenyloxy, C₁-C₈ alkylthio, halo-C₁-C₈ alkylthio, C₃-C₈ cycloalkylthio, C₂-C₈ alkenylthio, C₂-C₈ alkynylthio, C₁-C₈ alkylcarbonyl, halo-C₁-C₈ alkylcarbonyl, C₃-C₈ cycloalkylcarbonyl, C₂-C₈ alkenylcarbonyl, C₂-C₈ alkynylcarbonyl, C₁-C₈ alkoxy-C₁-C₈
 10 alkyl, cyano, nitro, hydroxy, mercapto, amino, C₁-C₈ alkylamino and C₁-C₈ dialkylamino.

More preferred optional substituents are C₁-C₄ alkyl, halo-C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl-C₁-C₄ alkyl, C₂-C₄ alkenyl, halo-C₂-C₄ alkenyl, C₃-C₆ cyclo-
 C₂-C₄ alkenyl, C₂-C₄ alkynyl, halo-C₂-C₄ alkynyl, C₁-C₄ alkoxy, halo-C₁-C₄ alkoxy, C₃-C₆ cycloalkoxy, C₂-C₄ alkenyloxy, halo-C₂-C₄ alkenyloxy, C₂-C₄ alkynyloxy, halo-C₂-C₄
 15 alkenyloxy, C₁-C₄ alkylthio, halo-C₁-C₄ alkylthio, C₃-C₆ cycloalkylthio, C₂-C₄ alkenylthio, C₂-C₄ alkynylthio, C₁-C₄ alkylcarbonyl, halo-C₁-C₄ alkylcarbonyl, C₃-C₆ cycloalkylcarbonyl, C₂-C₄ alkenylcarbonyl, C₂-C₄ alkynylcarbonyl, C₁-C₄ alkoxy-C₁-C₄ alkyl, cyano, nitro, hydroxy, mercapto, amino, C₁-C₄ alkylamino and C₁-C₄ dialkylamino.

More preferred optionally substituents are C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, halo-C₁-C₄ alkoxy, halogen, hydroxy, cyano, nitro and amino.

Typical examples for optionally substituted aryl include 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-cyanophenyl,
 25 3-cyanophenyl, 4-cyanophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2,3-dibromophenyl, 2,4-dibromophenyl, 2,5-dibromophenyl, 2,6-dibromophenyl, 3,4-dibromophenyl, 3,5-dibromophenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,3-dimethoxyphenyl, 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2,3-dicyanophenyl, 2,4-dicyanophenyl, 2,5-dicyanophenyl, 2,6-dicyanophenyl, 3,4-dicyanophenyl, 3,5-dicyanophenyl, 2,3-bis(trifluoromethyl)phenyl, 2,4-bis(trifluoromethyl)phenyl, 2,5-bis(trifluoromethyl)phenyl, 2,6-bis(trifluoromethyl)phenyl, 3,4-bis(trifluoromethyl)phenyl,

3,5-bis(trifluoromethyl)phenyl, 2,3-bis(trifluoromethoxy)phenyl, 2,4-bis(trifluoromethoxy)phenyl, 2,5-bis(trifluoromethoxy)phenyl, 2,6-bis(trifluoromethoxy)phenyl, 3,4-bis(trifluoromethoxy)phenyl, 3,5-bis(trifluoromethoxy)phenyl, 2-chloro-5-fluorophenyl, 2-fluoro-5-methylphenyl, 2-fluoro-5-methoxyphenyl, 5-chloro-2-fluorophenyl, 2-chloro-5-methylphenyl, 2-chloro-5-methoxyphenyl, 5-fluoro-2-methylphenyl, 5-chloro-2-methylphenyl, 5-methoxy-2-methylphenyl, 5-fluoro-2-methoxyphenyl, 5-chloro-2-methoxyphenyl and 2-methoxy-5-methylphenyl.

Typical examples for optionally substituted heteroaryl include 5-methyl-3-trifluoromethylpyrazol-1-yl, 3-methyl-5-trifluoromethylpyrazol-1-yl, 3,5-bis-trifluoromethylpyrazol-1-yl, 3,5-dimethylpyrazol-1-yl, 5-ethyl-3-trifluoromethylpyrazol-1-yl, 5-methyl-3-trifluoromethoxypyrazol-1-yl, 2-methyl-4-trifluoromethylimidazol-1-yl, 4-methyl-2-trifluoromethylimidazol-1-yl, 2,4-bis-trifluoromethylimidazol-1-yl, 2,4-dimethylimidazol-1-yl, 2-ethyl-4-trifluoromethylimidazol-1-yl, 2-methyl-4-trifluoromethoxyimidazol-1-yl, 5-methyl-3-trifluoromethyl[1,2,4]triazol-1-yl, 3-methyl-5-trifluoromethyl[1,2,4]triazol-1-yl, 3,5-bis-trifluoromethyl[1,2,4]triazol-1-yl and 3,5-dimethyl[1,2,4]triazol-1-yl, 5-ethyl-3-trifluoromethyl[1,2,4]triazol-1-yl, 5-methyl-3-trifluoromethoxy[1,2,4]triazol-1-yl.

Cycloalkyl on its own or as part of another substituent is, depending upon the number of carbon atoms mentioned, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

Alkoxy on its own or as part of another substituent is, depending upon the number of carbon atoms mentioned, for example methoxy, ethoxy, 1-propoxy, 2-propoxy, n-butoxy, 2-n-butoxy, or 2-tert-butoxy.

Alkenyl on its own or as part of another substituent is, depending upon the number of carbon atoms mentioned, for example, ethenyl, allyl, propen-1-yl, buten-2-yl, buten-3-yl, penten-1-yl, penten-3-yl, hexen-1-yl or 4-methyl-penten-3-yl.

Alkynyl on its own or as part of another substituent is, depending upon the number of carbon atoms mentioned, for example, ethynyl, propyn-1-yl, propyn-2-yl, butyn-1-yl, butyn-2-yl, 1-methyl-2-butynyl, hexyn-1-yl or 1-ethyl-2-butynyl.

Preferably, R^1 is difluoromethyl or trifluoromethyl;

Preferably R^2 is C_1 - C_8 alkyl, phenyl, or phenyl- C_1 - C_8 alkyl, wherein the alkyl, phenyl and phenylalkyl are each optionally substituted with one or more of, e.g. 1 to 3, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 alkoxy, halo- C_1 - C_4 alkoxy, halogen, hydroxy, cyano, nitro and amino. More preferably R^2 is C_1 - C_8 alkyl or C_1 - C_8 haloalkyl, phenyl or benzyl, wherein the phenyl and benzyl are each optionally substituted with halogen, e.g. 1 to 3

halogen atoms. Even more preferably R^2 is C_1 - C_6 alkyl, e.g. C_1 - C_4 alkyl. Most preferably R^2 is methyl or ethyl.

Preferably R^3 is methyl.

The processes according to the invention are suitable preferably for the preparation of compounds of formula I wherein R^1 is difluoromethyl or trifluoromethyl; R^2 is C_1 - C_6 alkyl, e.g. ethyl; and R^3 is methyl.


The processes according to the invention are especially suitable for the preparation of compounds of formula I wherein R^1 is difluoromethyl.

The processes according to the invention are very especially suitable for the preparation of compounds of formula I wherein R^1 is difluoromethyl, R^2 is ethyl, and R^3 is methyl.

The processes according to the invention are also very especially suitable for the preparation of compounds of formula I wherein R^1 is trifluoromethyl; R^2 is ethyl, and R^3 is methyl.

The compound of formula IV may be provided as a mixture comprising the compound of formula IV and the compound of formula I. For example, compounds of formula IV may be produced by N-alkylating the corresponding pyrazole. This will generally result in a mixture of compounds of formula IV and formula I. The present invention provides a process for increasing the proportion of the compound of formula I in a mixture comprising a compound of formula I and a compound of formula IV.

The compound of formula IV may be provided as a mixture comprising a compound of formula I and a compound of formula IV, and wherein said mixture is prepared by N-alkylating a compound of formula II:




wherein R^1 and R^2 are as defined for the compound of formula I; e.g. thereby producing a mixture comprising a compound of formula I and a compound of formula IV.

It may be advantageous in some cases to N alkylate the corresponding substituted pyrazole and isomerise any compound of formula IV produced from the alkylation

substantially at the same time, e.g. simultaneously. The reaction may be performed in one step.

Accordingly, in a further aspect, the invention provides a process, e.g. a regioselective process, for the preparation of a compound of formula I:




wherein R^1 is C_1 - C_4 haloalkyl;

R^2 is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl;

R^3 is methyl or ethyl;

comprising reacting a compound of formula II:



wherein R^1 and R^2 are as defined for the compound of formula I;


with an alkylating agent in the presence of an amide.

Preferred definitions of R^1 , R^2 and R^3 are the same as those given above. Most preferably R^1 is difluoromethyl, R^2 is C_1 - C_6 alkyl e.g. ethyl and R^3 is methyl.

Without being bound by theory, it is thought that the alkylating agent and the amide act as a catalyst to inter-convert the compound of formula I and the compound of formula IV, thereby promoting the proportions of the compounds of formula I and IV to thermodynamic equilibrium.

In a further aspect, the invention provides a process for inter-converting a compound of formula IV and a compound of formula I according to Scheme I:

Scheme I



wherein R^1 is C_1 - C_4 haloalkyl;


R^2 is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; and

5 R^3 is methyl or ethyl;

using an alkylating agent and an amide as inter-conversion reagents.

Preferred definitions of R^1 , R^2 and R^3 are the same as those given above. Most preferably R^1 is difluoromethyl, R^2 is C_1 - C_6 alkyl, e.g. ethyl, and R^3 is methyl.

Preferably the amide is a tertiary amide, e.g. a compound of formula XX:



wherein R^4 is H or C_1 - C_4 alkyl;

15 R^5 is C_1 - C_4 alkyl;

R^6 is C_1 - C_4 alkyl;


or R^4 and R^5 are together C_2 - C_5 alkyne;

or R^5 and R^6 are together C_2 - C_5 alkyne.

20 More preferably R^4 is H or C_1 - C_4 alkyl; R^5 is C_1 - C_4 alkyl; or R^4 and R^5 are together C_2 - C_5 alkyne; and R^6 is C_1 - C_4 alkyl. Most preferably the amide is N, N-dimethylformamide, N, N-dimethylacetamide or N-methyl-2-pyrrolidone.

Without being bound by theory it is understood that inter-conversion of the compound of formula I and IV proceeds via the pyrazolium cation. The alkylating agent is preferably a strong alkylating agent, e.g. one that is capable of alkylating a compound

of formula IV to form the corresponding pyrazolium cation, e.g. a compound of formula IVa




wherein R¹, R² and R³ are as defined for a compound of formula IV.

5

The alkylating agent and amide are present simultaneously in the reactions of the invention, e.g. as a mixture comprising the alkylating agent and amide. They may be added separately or simultaneously. When added simultaneously, if desired, they may be added as a salt, e.g. formed by alkylation of the amide by the alkylating agent.

10 Similarly, the amide and alkylating agent may form ions *in situ* arising from alkylation of the amide by the alkylating agent, thereby creating an "ionic liquid". In other words, the reactions of the invention may comprise a non-aqueous phase containing dispersed ions arising from alkylation of the amide by the alkylating agent.


15 The alkylating agent may be one that is capable of alkylating an amide, preferably a tertiary amide, e.g. to form a compound of formula XXa



wherein R⁴, R⁵ and R⁶ are as defined for a compound of formula XX and R³ is methyl or ethyl.

20

More preferably the alkylating agent is a compound of formula III:



wherein R³ is methyl or ethyl.

25 Preferably the reactions of the invention employ a methylating agent or ethylating agent, more preferably a methylating agent, e.g. a methylating agent this is capable of methylating a compound of formula IV and/or an amide such as a tertiary amide, e.g. a

compound of formula XX. More preferably the methylating agent is a compound of formula III in which R³ is methyl, e.g. dimethylsulphate.

5 In one embodiment the alkylating agent is dimethylsulphate and the amide is N, N-dimethylformamide. In another embodiment the alkylating agent is dimethylsulphate and the amide is N, N-dimethylacetamide. In another embodiment the alkylating agent is dimethylsulphate and the amide is N-methyl-2-pyrrolidone.

10 The reaction according to the invention can be carried out in an inert solvent, preferably an anhydrous inert solvent. Suitable solvents are, for example, xylene, mesitylene, tert-butyl benzene, chlorobenzene, 1,2-dichlorobenzene, Decalin, dibutyl ether, dipentyl ether, diphenyl ether and anisole. The reaction according to the invention is preferably carried out neat, e.g. without an additional solvent.

15 The temperature of the reaction in which the compound of formula IV is converted into the compound of formula I may be carried out at a temperature of e.g. 50 to 250°C, e.g. 100 to 200°C, e.g. 140 to 180°C. Preferably the reaction is performed at at least 100°C, at least 120°C, at least 140°C, at least 160°C. A person skilled in the art would be able to optimise the reaction to find the most suitable temperature.

20 The alkylating agent may be present in the reaction at 0.05 molar equivalents to 5 molar equivalents. We have found that increasing the concentration of alkylating agent increases the rate at which inter-conversion takes place, however larger amount of alkylating agent can affect yield. The amount of alkylating agent is preferably less than 25 1 molar equivalent. Preferably the alkylating agent is 0.2 molar equivalents to 0.7 molar equivalents, most preferably 0.3 molar equivalents to 0.5 molar equivalents. Equivalents are relative to the molar amount of the compound of formula IV or the compound of formula IV and compound of formula I when both are present.


30 The amide may be present in the reaction at 0.1 molar equivalents to 10 molar equivalents, preferably 0.2 molar equivalents to 2 molar equivalents, most preferably 0.5 molar equivalents to 1.5 molar equivalents. Equivalents are relative to the molar amount of the compound of formula IV or the compound of formula IV and the compound of formula I when both are present. In one embodiment the alkylating agent and amide are present in a catalytic amount.

35

WO 2008/145257 describes synthesis routes to N-alkylated substituted pyrazoles using methylhydrazine. The use of methylhydrazine instead of hydrazine allows synthesis of N-alkylated substituted pyrazoles in which a methyl group is placed on the desired pyrazole nitrogen atom thereby avoiding the need for a separate step for alkylation.

- 5 The present invention now provides an alkylation step that allows synthesis of the non-isomers with high regioselectivity. This makes a route involving hydrazine more feasible.

- 10 In a further aspect, the invention provides a process, e.g. a regioselective process, for the preparation of a compound of formula I:




wherein R¹ is C₁-C₄ haloalkyl;

R² is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; and

- 15 R³ is methyl or ethyl;

comprising

- a. reacting a compound of formula V:




- 20 wherein R¹ is C₁-C₄ haloalkyl;

R² is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; and

R⁷ is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl;

25

with hydrazine to produce a compound of formula II:




wherein R^1 and R^2 are as defined for formula I; and

- b. reacting the compound of formula II with an alkylating agent in the presence of
5 an amide.

Preferred definitions of R^1 , R^2 and R^3 are the same as those given above and R^7 is preferably hydrogen or C_1 - C_6 alkyl. Most preferably R^1 is difluoromethyl, R^2 is C_1 - C_6 alkyl e.g. ethyl, R^3 is methyl and R^7 is hydrogen or C_1 - C_6 alkyl e.g. ethyl. Preferably the
10 alkylating agent and amide are as described above.

In a further aspect alkylation of a compound of formula II and isomerisation may be carried out in separate steps. Accordingly, in a further aspect the invention provides a process, e.g. a regioselective process, for the preparation of a compound of formula
15 I:




wherein R^1 is C_1 - C_4 haloalkyl;

R^2 is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; and


20 R^3 is methyl or ethyl;

comprising

- b1. reacting a compound of formula II:



wherein R^1 and R^2 are as defined for the compound of formula I; with an alkylating agent to produce a mixture comprising a compound of formula I and a compound of formula IV







wherein R^1 , R^2 and R^3 are as defined for the compound of formula I; and

b2. reacting the mixture from b1. with an alkylating agent in the presence of an amide.

Preferred definitions of R^1 , R^2 and R^3 are the same as those given above. Most preferably R^1 is difluoromethyl, R^2 is C_1 - C_6 alkyl e.g. ethyl and R^3 is methyl.

The alkylating agent used in step b1. may or may not be the same as the alkylating agent used in step b2. Preferred alkylating agents for use in step b2 are described above. The alkylating agent used in step b1. may be selected from known alkylating agents. Suitable alkylating agents include for example alkyl phosphates, alkyl phosphonates, alkyl phosphites, alkyl sulphates and alkyl carbonates, for example a compound of formula III, XXI, XXII or XXIII:



wherein

R^3 is methyl or ethyl;


R^8 is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl, preferably hydrogen or C_1 - C_6 alkyl, e.g. ethyl; and

n is 0 or 1, preferably 1.

Preferred alkylating reagents are compounds of formula III and XXI, particularly alkylphosphates and alkylsulphonates. Dimethylsulphate and trimethylphosphate are particularly preferred. In one embodiment the alkylating reagent is dimethylsulphate, in another embodiment the alkylating reagent is trimethylphosphate. Alkylation may be performed in the presence of a base. Suitable bases are for example hydroxides and carbonates, e.g. of alkali metals. Methods of alkylating compounds of formula II are described for example in WO 2006/045504.


The compounds of formula II are known or can be prepared using hydrazine analogously to processes known in the literature. For example, such compounds can be prepared from the 3-oxo-carboxylic acid esters on which they are based by means of a two-step synthesis by reaction with trimethyl orthoformate and subsequent reaction with hydrazine. Such reactions are described, for example, in JP-2000-044541. A further synthesis route for the preparation of compounds of formula II is described in JP-2001-322983, wherein, for example, 3-trifluoromethyl-1H-pyrazole-4-carboxylic acid ethyl ester is prepared starting from 3-chloro-4,4,4-trifluoro-2-formyl-2-butenic acid ethyl ester by reaction with hydrazine. Also, WO 2006/045504 discusses procedures that may be employed for producing compounds of formula II from compounds of formula V using hydrazine. Compounds of formula III and XX are commercially available.

In a further aspect of the invention, there is provided use of an alkylating agent and an amide, e.g. as catalyst, in the conversion of a compound of formula IV:



wherein R¹ is C₁-C₄haloalkyl, R² is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; and R³ is methyl or ethyl;

into a compound of formula I:




wherein R¹, R² and R³ are as defined for the compound of formula IV.


Preferred definitions of R¹, R², and R³ are the same as those given above. Most preferably R¹ is difluoromethyl, R² is C₁-C₆ alkyl e.g. ethyl and R³ is methyl. Preferably the alkylating agent and amide are as described above.

In a further aspect there is provided a catalyst, e.g. for converting a compound of formula IV to a compound of formula I, comprising an alkylating agent and an amide.
 10 Preferably the alkylating agent and amide are as described above. Such a catalyst will usually exist as an ionic liquid.


In a further aspect of the invention there is provided a process, e.g. a regioselective process, for preparing a compound of formula VI:



15 comprising reacting a compound of formula VII:




with a compound of formula VIII:




20 in the presence of an amide selected from dimethylformamide, N, N-dimethylacetamide and N-methyl-2-pyrrolidone.

Compounds of formula I may be subsequently converted into the corresponding acid. Such compounds may also be useful intermediates in the production of fungicides, see e.g. WO 2008/145257. For example, compounds of formula I may be converted into compounds of formula IX:




wherein R¹ and R³ are as defined for the compound of formula I;
by hydrolysing the compound of formula I.

10 Accordingly, the invention provides a process for the preparation of a compound of formula IX:



wherein R¹ is C₁-C₄haloalkyl; and
R³ is methyl or ethyl;

15 comprising
1. preparing a compound of formula I:



wherein R¹ and R³ are as defined for the compound of formula IX; and
R² is optionally substituted alkyl, optionally substituted aryl or optionally substituted
20 heteroaryl;
according to the invention; and

2. hydrolysing the compound of formula I to produce the compound of formula IX.


Preferred definitions of R^1 , R^2 , and R^3 are the same as those given above. Most preferably R^1 is difluoromethyl, R^2 is C_1 - C_6 alkyl e.g. ethyl and R^3 is methyl.

5

Hydrolysis of the compound of formula I may be achieved by performing the steps:

- i) saponifying that compound in situ leading to the formation of a compound of formula I by
 - ii) adding a base to form the anion of the compound of formula IX;
 - 10 ii') adding an acid to form the compound of formula IX;
- e.g. as described in WO 2008/145257.

In a further aspect the invention provides a process for the preparation of a compound of formula X:



15

wherein R^1 is C_1 - C_4 haloalkyl;

R^3 is methyl or ethyl;


A is thienyl, phenyl, or ethylene each optionally substituted by one to three groups independently selected from halogen, methyl and methoxy;

20 B is a direct bond, cyclopropylene, an annelated bicyclo[2.2.1]heptane- or bicyclo[2.2.1]heptene ring;

D is hydrogen, halogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, C_1 - C_6 haloalkoxy, C_3 - C_6 cycloalkyl, C_1 - C_6 alkylidene, C_1 - C_6 haloalkylidene, phenyl or phenyl optionally substituted by one to three substituents independently selected from halogen and

25 trihalomethylthio;


comprising providing a compound of formula IX:



wherein R^1 is C_1 - C_4 haloalkyl and R^3 is methyl or ethyl;


according to the processes described above; and

reacting the compound of formula IX or the corresponding acid-halide with a compound of formula XI:



5 wherein A, B and D are as defined for the compound of formula X.

The compound of formula X is preferably a compound of formula XII (Isopyrazam), a compound of formula XIII (Sedaxane), a compound of formula XIV, a compound of formula XV (Penthiopyrad), a compound of formula XVI (Bixafen), a compound of
10 formula XVII (Fluxapyroxad), a compound of formula XVIII, or a compound of formula XIX:



The step of reacting the compound of formula IX or the corresponding acid-halide with a compound of formula XI may be performed according to known methods, e.g. as
15 described in WO 2004/035589 or WO 2009/135860. For example, the compound of formula IX may be treated with a halogenating agent, such as thionyl chloride, oxalyl


chloride, phosgene, SF₄, DAST, deoxofluor or thionylbromide to provide the acid-halogen, e.g. the acid chloride, which may then be reacted with the compound of formula XI in the presence of a suitable base, e.g. LiOH, KOH, NaOH, NEt₃, NaHCO₃, KHCO₃, Na₂CO₃ or K₂CO₃, e.g. in a solvent such as toluene, xylenes, dichloromethane, ethyl acetate or DMF, e.g. at -10°C to 30°C.

Isopyrazam, Sedaxane, Penthiopyrad, Fluxapyroxad and Bixafen are known fungicides. The compound of formula XIV is known, e.g. from WO 2007/048556, the compound of formula XVIII is known e.g. from WO 2010/000612, the compound of formula XIX is known e.g. from WO 2008/053044.

We have found that the compounds of formula I and IV have different boiling points which may be exploited to separate the compound of formula I from the compound of formula IV. Thus, the process may comprise separating a mixture of compounds of formula I and IV by distillation. For example, iso-DFPE has a boiling point of approximately 95°C/10mbar, whereas DFPE has a boiling point of approximately 120°C/1mbar. This separation step may be performed after completion of isomerisation or may be performed simultaneously with isomerisation, e.g. when the process is continuous. The compound of formula I may be purified by crystallisation.

Table 1 shows examples of compounds of formula I of the invention.

Table 1: Compounds of formula I



Comp. No.	R ₁	R ₂	R ₃
A1	CF ₂ H	CH ₂ CH ₃	CH ₃
A2	CF ₂ H	CH ₃	CH ₃
A3	CF ₂ H	CH ₃	CH ₂ CH ₃
A4	CF ₂ H	CH ₂ CH ₃	CH ₂ CH ₃
A5	CF ₃	CH ₂ CH ₃	CH ₃
A6	CF ₃	CH ₃	CH ₃
A7	CF ₃	CH ₃	CH ₂ CH ₃
A8	CF ₃	CH ₂ CH ₃	CH ₂ CH ₃

The present invention will now be described by way of the following non-limiting Examples. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques.

5

All references mentioned herein are incorporated by reference in their entirety. All aspects and preferred features of the invention may be combined with each other, except where this is evidently not possible.

10 **Figures****Figure 1**

Figure 1 shows that ethyl 5-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (iso-DFPE) reverts into ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (DFPE) under conditions according to the invention. The Y axis indicates the amount of DFPE as a proportion of the combined amount of DFPE and iso-DFPE. The X axis indicates time. Experimental details are described under Example 8. DMF is dimethylformamide, NMP is N-methyl-2-pyrrolidone, DMA is N, N-dimethylacetamide, DMS is dimethylsulphate. "DMF/DMS 0.5 equiv" means pre-formed DMF/DMS salt as described in Example 1, i.e., by treatment of 0.5 molar equivalents of DMF and 0.5 molar equivalents of DMS relative to the combined amount of DFPE and iso-DFPE.

15

Figure 2

Figure 2 shows that ethyl 5-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (iso-DFPE) reverts into ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (DFPE) under conditions according to the invention. The Y axis indicates the amount of DFPE as a proportion of the combined amount of DFPE and iso-DFPE. The X axis indicates time. Experimental details are described under Example 9.

20

25

Examples

Example 1:

Preparation of an amide/dimethylsulfate salt: dimethylsulfate (1 molar equivalent) and amide (1.2 molar equivalents), are heated to 70°C for 1.5 hours. Once cooled, the
5 resulting solution is available for use.

Example 2:

A solution of ethyl 5-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (iso-DFPE) (~98%, 56.1 g, 0.27 mol) and dimethylformamide (27.1 g, 0.37 mol) was stirred at room
10 temperature. Dimethylsulphate (12.1 g, 0.10 mol) was added. The resulting solution was heated gradually to 160°C and held for 4 hours. The solution was then heated gradually to 170°C over 30 minutes and held for additional 1.5 hours for a total reaction time of 6 hours at ≥160°C. Quantitative GC analysis of the reaction mass indicated the solution yields to be 49.8 g of ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-
15 carboxylate (DFPE) and 5.4 g of iso-DFPE.

Example 3:

A solution of ethyl 5-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (iso-DFPE) (>99%, 2.04 g, 0.01 mol), N, N-dimethylformamide /dimethylsulfate salt (1.00 g, 0.005
20 mol) and N, N-dimethylformamide (0.37 g, 0.005 mol) was stirred at room temperature. The resulting solution was heated gradually to 160°C and held for 7 hours. The conversion to ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (DFPE) was approximately 95.7%.

25 Example 4:

A solution of ethyl 5-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (iso-DFPE) (>99%, 2.04 g, 0.01 mol), N-methyl-2-pyrrolidone/dimethylsulfate salt (1.12 g, 0.005
mol) and N-methyl-2-pyrrolidone (0.50 g, 0.005 mol) was stirred at room temperature. The resulting solution was heated gradually to 160°C and held for 7 hours. The
30 conversion to ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (DFPE) was approximately 93.5%.

Example 5:

A solution of ethyl 5-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (iso-DFPE) (>99%, 2.04 g, 0.01 mol), N,N-dimethylacetamide /dimethylsulfate salt (1.06 g, 0.005
35 mol) and N,N-dimethylacetamide (0.44 mg, 0.005 mol) was stirred at room temperature. The resulting solution was heated gradually to 160°C and held for 7

hours. The conversion to ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (DFPE) was approximately 82.2%.

Example 6:

- 5 To 147.2 g of a crude mixture of ethyl 5-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (iso-DFPE) and ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (DFPE) (iso-DPFE: 50.1 g; DFPE: 85.3 g) was added 43.8 g of N,N-dimethylformamide and 12.6 g of dimethylsulfate. The resulting solution was heated gradually to 160°C and held for 4 hours. The solution was then heated gradually to
10 170°C over 30 minutes and held for an additional 1.5 hours for a total reaction time of 6 hours at ≥160°C. Quantitative GC analysis of the reaction mass indicated the solution yields to be 120.1 g of DFPE and 9.1 g of iso-DFPE. The unreacted iso-DFPE was then distilled out and recycled in the next batch. The crude product of DFPE from distillation bottom was dissolved in toluene and can be used directly for the next step,
15 e.g. hydrolysis, without any further purification.

Example 7:

- To 1.9 g of ethyl 3-difluoromethylpyrazole-4-carboxylate (NHDFPE) was added 2.5 g of N, N-dimethylformamide /dimethylsulfate salt. The mixture was heated to 160°C and
20 stirred for 7 hours. The isomer ratio of ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (DFPE): ethyl 5-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (iso-DFPE) at end of reaction time based on GC analysis was 98:2.

Example 8:

- 25 In each reactor of a multi-pot reaction block was placed 2.0 g (10 mmol) of ethyl 5-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (iso-DPFE) and amide/dimethylsulfate salt. The reaction block was heated to 170°C and stirred for 8 hours. Samples were taken periodically for GC analysis. Results are shown in Figure 1.


30

Example 9:

- In each reactor of a multi-pot reaction block was placed 2.0 g (10 mmol) of ethyl 5-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate (iso-DPFE), DMF/dimethylsulfate salt (1.0-2.5 mmol) , and 0.7 g DMF (10 mmol). The reaction block was heated to
35 150°C and stirred for 8 hours. Samples were taken periodically for GC analysis. Results are shown in Figure 2.

What is claimed is:

1. A process for the preparation of a compound of formula I:




wherein R¹ is C₁-C₄ haloalkyl;

R² is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; and

R³ is methyl or ethyl;

comprising reacting a compound of formula IV:




wherein R¹, R² and R³ are as defined for the compound of formula I;

with an alkylating agent in the presence of an amide.

2. A process according to claim 1, wherein the process is for increasing the proportion of a compound of formula I in a mixture comprising a compound of formula I and a compound of formula IV.


3. A process for the preparation of a compound of formula I:



wherein R¹ is C₁-C₄ haloalkyl;

R^2 is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; and
 R^3 is methyl or ethyl;

5 comprising reacting a compound of formula II:




wherein R^1 and R^2 are as defined for the compound of formula I;

with an alkylating agent in the presence of an amide.

10

4. A process for inter-converting a compound of formula IV and a compound of formula I according to Scheme I:

Scheme I



wherein R^1 is C_1 - C_4 haloalkyl;


15 R^2 is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; and
 R^3 is methyl or ethyl;

using an alkylating agent and an amide as inter-conversion reagents.

20

5. A process according to any one of claims 1 to 4, wherein the amide is a tertiary amide.

6. A process according to any one of claims 1 to 5, wherein the amide is a
 25 compound of formula XX:



wherein R^4 is H or $\text{C}_1\text{-C}_4$ alkyl;

R^5 is $\text{C}_1\text{-C}_4$ alkyl;


R^6 is $\text{C}_1\text{-C}_4$ alkyl;

- 5 or R^4 and R^5 together are $\text{C}_2\text{-C}_5$ alkyene;
or R^5 and R^6 are together $\text{C}_2\text{-C}_5$ alkyene.

7. A process according to any one of claims 1 to 6, wherein the amide is dimethylformamide, N-methyl-2-pyrrolidone or N, N-dimethylacetamide.


10

8. A process according to any one of claims 1 to 7, wherein the alkylating agent is capable of alkylating a compound of formula IV as defined in claim 1 to form a compound of formula IVa




- 15 wherein R^1 , R^2 and R^3 are as defined for a compound of formula IV in claim 1.

9. A process according to any one of claims 1 to 8, wherein the alkylating agent is a compound of formula III:




- 20 wherein R^3 is methyl or ethyl.


10. A process according to any one of claims 1 to 9, wherein the process is for preparing a compound of formula VI:



comprising reacting a compound of formula VII:




5 with a compound of formula VIII:



in the presence of an amide selected from dimethylformamide, N-methyl-2-pyrrolidone and N, N-dimethylacetamide.

10 11. A process for the preparation of a compound of formula I:




wherein R¹ is C₁-C₄ haloalkyl;

R² is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; and


15 R³ is methyl or ethyl;

comprising

b1. reacting a compound of formula II:




wherein R^1 and R^2 are as defined for the compound of formula I; with an alkylating agent to produce a mixture comprising a compound of formula I and a compound of formula IV



wherein R^1 , R^2 and R^3 are as defined for the compound of formula I; and

b2. reacting the mixture from b1. with an alkylating agent in the presence of an amide.


12. A process for the preparation of a compound of formula IX:



wherein R^1 is C_1 - C_4 haloalkyl, and
 R^3 is methyl or ethyl;

comprising

1. preparing a compound of formula I:



wherein R^1 and R^3 are as defined for the compound of formula IX; and


R^2 is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl;

as defined in any one of claims 1 to 11; and

5

2. hydrolysing the compound of formula I to produce the compound of formula IX.

13. A process for the preparation of a compound of formula X:



10 wherein R^1 is C_1 - C_4 haloalkyl;

R^3 is methyl or ethyl;


A is thienyl, phenyl, or ethylene each optionally substituted by one to three groups independently selected from halogen, methyl and methoxy;

B is a direct bond, cyclopropylene, an annelated bicyclo[2.2.1]heptane- or

15 bicyclo[2.2.1]heptene ring;

D is hydrogen, halogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, C_1 - C_6 haloalkoxy, C_3 - C_6 cycloalkyl, C_1 - C_6 alkylidene, C_1 - C_6 haloalkylidene, phenyl or phenyl optionally substituted by one to three substituents independently selected from halogen and trihalomethylthio;

20 comprising providing a compound of formula IX:




wherein R^1 is C_1 - C_4 haloalkyl and R^3 is methyl or ethyl;

according to the process as defined in claim 12; and


reacting the compound of formula IX or the corresponding acid-halide with a compound

25 of formula XI:



wherein A, B and D are as defined for the compound of formula X.

14. A process according to claim 13, wherein the compound of formula X is a compound of formula XII (Isopyrazam), a compound of formula XIII (Sedaxane), a compound of formula XIV, a compound of formula XV (Penthiopyrad), a compound of formula XVI (Bixafen), a compound of formula XVII (Fluxapyroxad), a compound of formula XVIII, or a compound of formula XIX:



15. A process according to any one of claims 1 to 14, wherein
- R¹ is difluoromethyl or trifluoromethyl;
 - R² is C₁-C₆ alkyl; and
 - R³ is methyl.

1/1




Figure 1




Figure 2

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2011/063360

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D231/14
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2008/141020 A1 (LILLY CO ELI [US]; BADESCU VALENTINA O [US]; CAMP ANNE MARIE [GB]; CLA) 20 November 2008 (2008-11-20)	3,5-8
A	preparation 35	1,2,9-15
A	----- WO 2006/045504 A1 (SYNGENTA PARTICIPATIONS AG [CH]; WALTER HARALD [CH]; CORSI CAMILLA [CH] 4 May 2006 (2006-05-04) cited in the application claims 1-4	1-15
A	----- WO 2008/145257 A1 (SYNGENTA PARTICIPATIONS AG [CH]; GIORDANO FANNY [CH]; VETTIGER THOMAS) 4 December 2008 (2008-12-04) cited in the application claim 1	1-15
	----- -/--	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 November 2011

Date of mailing of the international search report

10/11/2011

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Fanni, Stefano

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2011/063360

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2008/003452 A1 (ORGANON NV [NL]; GILLEN KEVIN JAMES [GB]; JAMIESON CRAIG [GB]; MACLEAN) 10 January 2008 (2008-01-10)	3,5-8
A	scheme 1 example 50 -----	1,2,4, 9-15
X	WO 2009/147167 A1 (ORGANON NV [NL]; GILLESPIE JONATHAN [GB]; JAMIESON CRAIG [GB]; MACLEAN) 10 December 2009 (2009-12-10)	3,5-8
A	example 46 -----	1,2,4, 9-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2011/063360

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2008141020	A1	20-11-2008	
		AU 2008251584 A1	20-11-2008
		CA 2684563 A1	20-11-2008
		CN 101861312 A	13-10-2010
		EA 200971052 A1	30-04-2010
		EP 2155717 A1	24-02-2010
		JP 2010526819 A	05-08-2010
		KR 20090127436 A	11-12-2009
		US 2010120785 A1	13-05-2010
		WO 2008141020 A1	20-11-2008
WO 2006045504	A1	04-05-2006	
		AR 051936 A1	21-02-2007
		AU 2005298922 A1	04-05-2006
		BR PI0516994 A	30-09-2008
		CA 2582141 A1	04-05-2006
		CN 101044119 A	26-09-2007
		EA 200700767 A1	26-10-2007
		EP 1805145 A1	11-07-2007
		JP 2008517019 A	22-05-2008
		KR 20070067163 A	27-06-2007
		US 2009069572 A1	12-03-2009
		WO 2006045504 A1	04-05-2006
		ZA 200702516 A	25-09-2008
WO 2008145257	A1	04-12-2008	
		AR 066709 A1	09-09-2009
		AU 2008255284 A1	04-12-2008
		CA 2687176 A1	04-12-2008
		CN 101679281 A	24-03-2010
		CR 11129 A	27-01-2010
		EC SP099768 A	28-12-2009
		EP 2150536 A1	10-02-2010
		JP 2010528071 A	19-08-2010
		KR 20100017431 A	16-02-2010
		RU 2009148884 A	10-07-2011
		TW 200914427 A	01-04-2009
		US 2010174093 A1	08-07-2010
		WO 2008145257 A1	04-12-2008
WO 2008003452	A1	10-01-2008	
		AR 061792 A1	24-09-2008
		AU 2007271469 A1	10-01-2008
		CA 2655680 A1	10-01-2008
		CN 101484448 A	15-07-2009
		EP 2041124 A1	01-04-2009
		JP 2009541404 A	26-11-2009
		KR 20090027672 A	17-03-2009
		NZ 573325 A	27-05-2011
		PE 03782008 A1	25-04-2008
		TW 200817385 A	16-04-2008
		US 2008255086 A1	16-10-2008
		WO 2008003452 A1	10-01-2008
		ZA 200810165 A	30-09-2009
WO 2009147167	A1	10-12-2009	
		AR 072052 A1	04-08-2010
		AU 2009253889 A1	10-12-2009
		CA 2725538 A1	10-12-2009
		CN 102056904 A	11-05-2011
		EP 2297110 A1	23-03-2011
		JP 2011523656 A	18-08-2011
		TW 201012803 A	01-04-2010

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2011/063360

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1, 2, 4(completely); 5-15(partially)

processes for preparing present compound of formula I involving the present compound of formula IV and an alkylating agent in the presence of an amide.

2. claims: 3(completely); 5-15(partially)

process for preparing present compound of formula I via the alkylation of present compound of formula II with an alkylating agent in the presence of an amide

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2011/063360

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 2011092539 A1	21-04-2011
		W0 2009147167 A1	10-12-2009
